Literature DB >> 23485522

Contrast enhanced CT-scan to diagnose intrahepatic cholangiocarcinoma in patients with cirrhosis.

Massimo Iavarone1, Fabio Piscaglia, Sara Vavassori, Marzia Galassi, Angelo Sangiovanni, Laura Venerandi, Laura Virginia Forzenigo, Rita Golfieri, Luigi Bolondi, Massimo Colombo.   

Abstract

BACKGROUND & AIMS: Contrast enhanced computed tomography (CT-scan) is a standard of care for the radiological diagnosis of hepatocellular carcinoma (HCC) in patients with cirrhosis. This technique, however, is not validated to exclude intrahepatic cholangiocarcinoma (ICC) which may develop in patients with cirrhosis, as well.
METHODS: To assess the features of contrast CT-scan in the diagnosis of ICC, we reviewed all CT-scan films obtained in cirrhotic patients with a histologically documented ICC, taking in consideration the pattern and dynamics of the arterial, portal venous and delayed phases of contrast uptake.
RESULTS: Thirty-two patients had 40 nodules of ICC (22 male; median age 62years; 13 hepatitis C) that were identified either during surveillance with abdominal ultrasound (21 patients, 66%) or incidentally (11 patients, 34%). ICC was either multifocal or ≥ 30 mm in 11 of the former and 10 of the latter group (52% vs. 91%, p<0.05). Two nodules (5%) escaped detection by CT-scan, while the remaining 38 showed a heterogeneous contrast enhancement pattern, being the arterial peripheral-rim enhancement present in 19 (50%) cases and a progressive homogeneous contrast uptake in 16 (42%) cases during the three vascular phases, with no relation to tumor size. Importantly, all nodules lacked the radiological hallmark of HCC, the only ICC nodule showing a homogeneous wash-in during the arterial phase followed by a wash-out in the delayed venous phase, however showing a homogeneous wash-in during the portal phase too.
CONCLUSIONS: ICC in cirrhotic patients displays distinct vascular patterns at CT-scan that allow for differentiation from HCC.
Copyright © 2013 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23485522     DOI: 10.1016/j.jhep.2013.02.013

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  43 in total

1.  Gastric sub-epithelial tumors: identification of gastrointestinal stromal tumors using CT with a practical scoring method.

Authors:  Ming Liu; Liheng Liu; Erhu Jin
Journal:  Gastric Cancer       Date:  2018-12-09       Impact factor: 7.370

2.  The challenges of novel contrast agents for the imaging diagnosis of hepatocellular carcinoma.

Authors:  Carmen Ayuso; Jordi Bruix
Journal:  Hepatol Int       Date:  2013-12-28       Impact factor: 6.047

3.  Focal lesions in cirrhotic liver: what else beyond hepatocellular carcinoma?

Authors:  Massimo Galia; Adele Taibbi; Daniele Marin; Alessandro Furlan; Marco Dioguardi Burgio; Francesco Agnello; Giuseppe Cabibbo; Bernard E Van Beers; Tommaso Vincenzo Bartolotta; Massimo Midiri; Roberto Lagalla; Giuseppe Brancatelli
Journal:  Diagn Interv Radiol       Date:  2014 May-Jun       Impact factor: 2.630

4.  Predicting IDH mutation status of intrahepatic cholangiocarcinomas based on contrast-enhanced CT features.

Authors:  Yong Zhu; Jun Chen; Weiwei Kong; Liang Mao; Wentao Kong; Qun Zhou; Zhengyang Zhou; Bin Zhu; Zhongqiu Wang; Jian He; Yudong Qiu
Journal:  Eur Radiol       Date:  2017-07-27       Impact factor: 5.315

5.  Hepatobiliary Quiz Answers - 18 (2016).

Authors:  Sahaj Rathi; Radha K Dhiman
Journal:  J Clin Exp Hepatol       Date:  2016-07-25

Review 6.  Cholangiocarcinoma - evolving concepts and therapeutic strategies.

Authors:  Sumera Rizvi; Shahid A Khan; Christopher L Hallemeier; Robin K Kelley; Gregory J Gores
Journal:  Nat Rev Clin Oncol       Date:  2017-10-10       Impact factor: 66.675

Review 7.  The treatment of cholangiocarcinoma: a hepatologist's perspective.

Authors:  Kamran Qureshi; Randhir Jesudoss; Abdullah M S Al-Osaimi
Journal:  Curr Gastroenterol Rep       Date:  2014-10

Review 8.  Cholangiocarcinoma.

Authors:  Nataliya Razumilava; Gregory J Gores
Journal:  Lancet       Date:  2014-02-26       Impact factor: 79.321

Review 9.  Evidence Supporting LI-RADS Major Features for CT- and MR Imaging-based Diagnosis of Hepatocellular Carcinoma: A Systematic Review.

Authors:  An Tang; Mustafa R Bashir; Michael T Corwin; Irene Cruite; Christoph F Dietrich; Richard K G Do; Eric C Ehman; Kathryn J Fowler; Hero K Hussain; Reena C Jha; Adib R Karam; Adrija Mamidipalli; Robert M Marks; Donald G Mitchell; Tara A Morgan; Michael A Ohliger; Amol Shah; Kim-Nhien Vu; Claude B Sirlin
Journal:  Radiology       Date:  2017-11-21       Impact factor: 11.105

10.  Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA).

Authors:  Jesus M Banales; Vincenzo Cardinale; Guido Carpino; Marco Marzioni; Jesper B Andersen; Pietro Invernizzi; Guro E Lind; Trine Folseraas; Stuart J Forbes; Laura Fouassier; Andreas Geier; Diego F Calvisi; Joachim C Mertens; Michael Trauner; Antonio Benedetti; Luca Maroni; Javier Vaquero; Rocio I R Macias; Chiara Raggi; Maria J Perugorria; Eugenio Gaudio; Kirsten M Boberg; Jose J G Marin; Domenico Alvaro
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-04-20       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.